SSA
KROS icon

Schonfeld Strategic Advisors’s Keros Therapeutics KROS Stock Holding History

Schonfeld Strategic Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,558
Closed -$159K – 2300
2025
Q1 		$159K Buy
+15,558
New +$181K ﹤0.01% 1967
2024
Q4 		– Sell
-199,354
Closed -$11.6M – 2215
2024
Q3 		$11.6M Buy
199,354
+165,241
+484% +$8.16M 0.08% 262
2024
Q2 		$1.56M Sell
34,113
-26,292
-44% -$1.41M 0.01% 1009
2024
Q1 		$4M Sell
60,405
-34,933
-37% -$2.07M 0.03% 728
2023
Q4 		$3.79M Buy
95,338
+17,538
+23% +$550K 0.03% 591
2023
Q3 		$2.48M Sell
77,800
-8,927
-10% -$333K 0.02% 763
2023
Q2 		$3.48M Buy
86,727
+30,182
+53% +$1.32M 0.03% 589
2023
Q1 		$2.41M Buy
56,545
+16,245
+40% +$820K 0.02% 641
2022
Q4 		$1.94M Buy
+40,300
New +$1.88M 0.02% 834
2022
Q2 		– Sell
-18,097
Closed -$984K – 2774
2022
Q1 		$984K Buy
18,097
+2,053
+13% +$105K 0.01% 999
2021
Q4 		$939K Buy
+16,044
New +$800K 0.01% 976
2021
Q2 		– Sell
-17,046
Closed -$1.05M – 2127
2021
Q1 		$1.05M Buy
+17,046
New +$1.08M 0.01% 871

Other funds holding KROS

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Schonfeld Strategic Advisors's KROS Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Keros Therapeutics (KROS) in Q2 2025, closing a stake of 15,558 shares — an estimated $159K sold.

Schonfeld Strategic Advisors first reported a position in KROS in Q1 2021 and held it in 12 quarters. The position peaked at $11.6M in Q3 2024. 139 funds tracked by Wall St. Rank hold KROS as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Keros Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 15,558 Keros Therapeutics shares in Q2 2025, an estimated $159K.
  • Schonfeld Strategic Advisors first reported a position in Keros Therapeutics in Q1 2021 and held it in 12 quarters.
  • Schonfeld Strategic Advisors's Keros Therapeutics position peaked at $11.6M in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.